Novo Nordisk Faces Critical Market Test with Q4 Results
Published on 02/02/2026 at 05:07 | Redaktion boerse-global.de
All eyes are on Danish pharmaceutical giant Novo Nordisk this week as it prepares to release its fourth-quarter 2025 financial results. The report, due Wednesday, arrives at a pivotal moment marked by intensifying competition in the lucrative GLP-1 drug market and the recent U.S. launch of a key new product.
The company will publish its Q4 2025 figures on February 4, 2026, prior to the opening of the Copenhagen market. A conference call and live webcast for investors will follow at 13:00 CET.
Market consensus, as compiled by Zacks, anticipates quarterly revenue of $11.96 billion and earnings per share (EPS) of $0.89. A year-over-year decline in the Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
